Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30807652 | 1.00 | ALDH1A1 (0.44) | ALDH1A1ALOX15CYP1A2HSD17B10CDC25A | |
| SCHEMBL9996737 | 0.81 | RXRB (0.45) | ALDH1A1CYP1A2HSD17B10CA2KDM4E | |
| SCHEMBL362047 | 0.81 | CES2 (0.41) | ALDH1A1CYP1A2CA1CA2TSHR | |
| SCHEMBL28989529 | 0.81 | HSD17B10 (0.41) | HSD17B10TDP1L3MBTL1CA1CA2 | |
| SCHEMBL787718 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TDP1MEN1KMT2APOLB | |
| SCHEMBL396220 | 0.81 | TSHR (0.59) | ALDH1A1CYP1A2HSD17B10TDP1MEN1 | |
| SCHEMBL14283158 | 0.81 | ALDH1A1 (0.50) | ALDH1A1ALOX15CYP1A2HSD17B10CDC25B | |
| SCHEMBL733036 | 0.81 | KDM4E (0.44) | CA1CA2TTRENPP2KDM4E | |
| SCHEMBL18241272 | 0.81 | CA2 (0.41) | ALDH1A1HSD17B10POLBCA2TSHR | |
| SCHEMBL29825352 | 0.81 | KDM4E (0.44) | CA1CA2TTRENPP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119455064-A | Injectable self-adhesive gel and preparation method and application thereof | 浙江大学 | 2025-02-18 | — | — | CN | claimed |
| CN-115851267-A | Dual-emission room temperature phosphorescent material and preparation method and application thereof | 武汉大学 | 2023-03-28 | — | — | CN | claimed |
| EP-2449370-B1 | ANALYSIS AND ASSAY OF GLYCATED HEMOGLOBINS BY CAPILLARY ELECTROPHORESIS, BUFFER COMPOSITIONS, AND KITS FOR CAPILLARY ELECTROPHORESIS | SEBIA SA (FR) | 2020-03-11 | — | — | EP | claimed |
| US-10119933-B2 | Analysis and assay of glycated haemoglobins by capillary electrophoresis, buffer compositions and kits for capillary electrophoresis | SEBIA (FR) | 2018-11-06 | — | — | US | claimed |
| US-20160077052-A1 | ANALYSIS AND ASSAY OF GLYCATED HAEMOGLOBINS BY CAPILLARY ELECTROPHORESIS, BUFFER COMPOSITIONS AND KITS FOR CAPILLARY ELECTROPHORESIS | SEBIA (FR) | 2016-03-17 | — | — | US | claimed |
| US-9222913-B2 | Analysis and assay of glycated haemoglobins by capillary electrophoresis, buffer compositions and kits for capillary electrophoresis | SEBIA (FR) | 2015-12-29 | — | — | US | claimed |
| US-20110000788-A1 | ANALYSIS AND ASSAY OF GLYCATED HAEMOGLOBINS BY CAPILLARY ELECTROPHORESIS, BUFFER COMPOSITIONS AND KITS FOR CAPILLARY ELECTROPHORESIS | SEBIA (FR) | 2011-01-06 | — | — | US | claimed |
| CN-119455064-A | Injectable self-adhesive gel and preparation method and application thereof | 浙江大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-115851267-B | Double-emission room-temperature phosphorescent material and preparation method and application thereof | 武汉大学 | 2024-10-08 | — | — | CN | disclosed |
| CN-114269756-B | 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E | 效应疗法股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-103038245-B | Modified c-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL MYERS SQUIBB CO | 2015-03-25 | — | — | CN | disclosed |
| US-8754068-B2 | Modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2576585-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-04-10 | — | — | EP | disclosed |
| CN-103038245-A | Modified c-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL MYERS SQUIBB CO | 2013-04-10 | — | — | CN | disclosed |
| US-20120142707-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| WO-2011153315-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20110000788-A1 | ANALYSIS AND ASSAY OF GLYCATED HAEMOGLOBINS BY CAPILLARY ELECTROPHORESIS, BUFFER COMPOSITIONS AND KITS FOR CAPILLARY ELECTROPHORESIS | SEBIA (FR) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | ALDH1A1 3610/4885ALOX15 3208/4885CYP1A2 852/4885 |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | HAVCR2, HDGF, SLC10A1 | ALDH1A1 3377/4885ALOX15 3088/4885CYP1A2 786/4885 |
| US-20110000788-A1 | ANALYSIS AND ASSAY OF GLYCATED HAEMOGLOBINS BY CAPILLARY ELECTROPHORESIS, BUFFER COMPOSITIONS AND KITS FOR CAPILLARY ELECTROPHORESIS | HBB, HBG1, HBG2 | ALDH1A1 3297/4885ALOX15 4358/4885CYP1A2 4555/4885 |
| US-20120142707-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BET1, BIRC3, CYTH3 | ALDH1A1 4247/4885ALOX15 1702/4885CYP1A2 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.